Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces that it entered into a number of new research collaboration agreements since its May 2010. During this period, collaboration agreements has been executed with multiple top-20 biopharmaceutical companies, as well as with multiple biotech companies.
ADCs are being evaluated by the company's collaborators in which the newest Syntarga Linker-Drug chemistries are linked to collaborator antibodies. The company has recently presented biological data for its current ADC chemistries at international conferences.
“The exciting data generated for ADCs based on our optimized Linker-Drugs vis-à-vis multiple established technologies, with regards to both efficacy and safety, have triggered significant interest from top-tier (bio)pharma players. The growing package of biological data for ADCs based on Syntarga technology against a variety of antigen targets underscores the broad potential of the Company’s unique, proprietary technologies.” said Dr Vincent de Groot, chief executive officer of Syntarga.
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate technology and products for the treatment of cancer.